Use of cerebrospinal fluid biomarkers in diagnosis of dementia across Europe

European Journal of Neurology

Volumn 17, Issue 1, 2010, Pages 90-96

  Hort, J ^a   Bartos, A ^b,c   Pirttila T ^d   Scheltens, P ^e  

^a UNIVERSITY HOSPITAL MOTOL   (Czech Republic)

^b NATIONAL INSTITUTE OF MENTAL HEALTH   (Czech Republic)

^c CHARLES UNIVERSITY   (Czech Republic)

^d KUOPIO UNIVERSITY HOSPITAL   (Finland)

^e VU UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Alzheimer's disease; Beta amyloid; Biomarker; Cerebrospinal fluid; Phosphorylated tau; Total tau

Indexed keywords

AMYLOID BETA PROTEIN; BIOLOGICAL MARKER; PHOSPHORYLATED TAU PROTEIN; TAU PROTEIN; UNCLASSIFIED DRUG;

ALZHEIMER DISEASE; ARTICLE; CEREBROSPINAL FLUID ANALYSIS; ENZYME LINKED IMMUNOSORBENT ASSAY; EUROPE; HUMAN; NORMAL VALUE; PRIORITY JOURNAL; PROTEIN CEREBROSPINAL FLUID LEVEL; QUESTIONNAIRE;

ADULT; AGED; AMYLOID BETA-PROTEIN; BIOLOGICAL MARKERS; BRAIN; DEMENTIA; EUROPE; FEMALE; HUMANS; MALE; MIDDLE AGED; PHOSPHORYLATION; PREDICTIVE VALUE OF TESTS; PROGNOSIS; SENSITIVITY AND SPECIFICITY; TAU PROTEINS; YOUNG ADULT;

EID: 73449137232     PISSN: 13515101     EISSN: 14681331     Source Type: Journal    
DOI: 10.1111/j.1468-1331.2009.02753.x     Document Type: Article

References (17)

1. Petrovitch H, White LR, Ross GW, et al. Accuracy of clinical criteria for AD in the Honolulu-Asia Aging Study, a population-based study. Neurology 2001 57 : 226 234.
2. McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology 1984 34 : 939 944.
3. Dubois B, Feldman HH, Jacova C, et al. Research criteria for the diagnosis of Alzheimer's disease: revising the NINCDS-ADRDA criteria. Lancet Neurol 2007 6 : 734 746.
4. Frankfort SV, van Campen JP, Tulner LR, Beijnen JH. Serum amyloid beta peptides in patients with dementia and age-matched non-demented controls as detected by surface-enhanced laser desorption ionisation-time of flight mass spectrometry (SELDI-TOF MS). Curr Clin Pharmacol 2008 3 : 144 154.
5. Schoonenboom NS, van der Flier WM, Blankenstein MA, et al. CSF and MRI markers independently contribute to the diagnosis of Alzheimer's disease. Neurobiol Aging 2008 29 : 669 675.
6. Sluimer JD, Bouwman FH, Vrenken H, et al. Whole-brain atrophy rate and CSF biomarker levels in MCI and AD: a longitudinal study. Neurobiol Aging 2008 in press.
7. Bouwman FH, van der Flier WM, Schoonenboom NS, et al. Longitudinal changes of CSF biomarkers in memory clinic patients. Neurology 2007 69 : 1006 1011.
8. Sjogren M, Vanderstichele H, Agren H, et al. Tau and Abeta42 in cerebrospinal fluid from healthy adults 21-93 years of age: establishment of reference values. Clin Chem 2001 47 : 1776 1781.
9. Herukka SK, Hallikainen M, Soininen H, Pirttila T. CSF Abeta42 and tau or phosphorylated tau and prediction of progressive mild cognitive impairment. Neurology 2005 64 : 1294 1297.
10. Vanderstichele H, De Vreese K, Blennow K, et al. Analytical performance and clinical utility of the INNOTEST PHOSPHO-TAU181P assay for discrimination between Alzheimer's disease and dementia with Lewy bodies. Clin Chem Lab Med 2006 44 : 1472 1480.
11. Hansson O, Zetterberg H, Buchhave P, Londos E, Blennow K, Minthon L. Association between CSF biomarkers and incipient Alzheimer's disease in patients with mild cognitive impairment: a follow-up study. Lancet Neurol 2006 5 : 228 234.
12. Hort J, Glosova L, Vyhnalek M, Bojar M, Skoda D, Hladikova M. Tau protein a beta amyloid v likvoru u Alzheimerovy choroby. Cesk Slov Neurol N 2007 70 : 30 36.
13. Kapaki E, Paraskevas GP, Papageorgiou SG, et al. Diagnostic value of CSF biomarker profile in frontotemporal lobar degeneration. Alzheimer Dis Assoc Disord 2008 22 : 47 53.
14. Verwey N, Bouwman F, van der Flier W, Veerhuis R, Scheltens P, Blankenstein M. Variability in longitudinal CSF tau and phosphorylated tau measurements. Clin Chem Lab Med 2008 46 : 1300 1304.
15. Bateman RJ, Wen G, Morris JC, Holtzman DM. Fluctuations of CSF amyloid-beta levels: implications for a diagnostic and therapeutic biomarker. Neurology 2007 68 : 666 669.
16. Schoonenboom NS, Mulder C, Vanderstichele H, et al. Effects of processing and storage conditions on amyloid beta (1-42) and tau concentrations in cerebrospinal fluid: implications for use in clinical practice. Clin Chem 2005 51 : 189 195. Epub 2004 Nov 11.
17. Fagan AM, Roe CM, Xiong CJ, et al. Cerebrospinal fluid tau/beta-amyloid(42) ratio as a prediction of cognitive decline in nondemented older adults. Arch Neurol 2007 64 : 343 349.